Hoth Therapeutics Alzheimer's Treatment Shows Improvement In Cognitive Function, Anxiety
Portfolio Pulse from Vandana Singh
Hoth Therapeutics Inc announced positive preclinical endpoints for its Alzheimer's Disease therapeutic, HT-ALZ. The treatment showed improvements in cognitive function tests and reduced anxiety-like behavior in mice. The study was conducted at Washington University, St. Louis. HOTH shares are up 6.20% at $2.39 on the last check Wednesday.
August 09, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hoth Therapeutics' Alzheimer's treatment, HT-ALZ, shows positive preclinical results. This news has led to a 6.20% increase in HOTH shares.
The positive preclinical results for Hoth Therapeutics' Alzheimer's treatment, HT-ALZ, is a significant development for the company. This news has likely contributed to the 6.20% increase in HOTH shares, indicating investor confidence in the potential success of the treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100